Literature DB >> 2476404

Influence of interferon on adriamycin uptake of cultured tumor cells.

K Yoneda1, T Yamamoto, T Osaki.   

Abstract

Effect of human interferon beta (IFN beta) or interferon gamma (IFN gamma) on cellular uptake of adriamycin (ADM) was measured in 3 in vitro-cultured human tumor cell lines. Pre-incubation of tumor cells with 100 IU/ml of IFN beta or gamma for 6 hr resulted in an increased intracellular ADM concentration, but ADM efflux was not affected by the IFNs. The increase in cellular uptake of ADM was in agreement with both DNA and protein synthesis inhibition. 3H thymidine (3H-TdR) incorporation was remarkably inhibited by ADM with pre-treatment of 100 IU/ml of each IFN, and an additive effect of ADM and IFN on cell growth inhibition could be observed. Similar additive inhibition against tumor-cell proliferation in nude mice, which received combined treatment (twice/week) of IFN gamma (5,000 IU/mouse) and ADM (5-20 micrograms/mouse), was also observed. These results indicate that IFN increases cellular influx of ADM, and antiproliferative activity against tumor cells is enhanced by a combination of IFN and ADM.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2476404     DOI: 10.1002/ijc.2910440318

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

Review 1.  Biological response modifiers in the management of patients with breast cancer.

Authors:  D L Longo; L C Hartmann
Journal:  Breast Cancer Res Treat       Date:  1990-09       Impact factor: 4.872

2.  Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines.

Authors:  Z Gazit; D W Weiss; D Shouval; M Yechezkeli; V Schirrmacher; M Notter; J Walter; E Kedar
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

3.  Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells.

Authors:  E Kedar; Y Rutkowski; B Leshem
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  Phase II study of high-dose epirubicin, lonidamine, alpha 2b interferon in advanced breast cancer.

Authors:  R V Iaffaioli; A Tortoriello; G Facchini; M Santangelo; L Bucci; L Fei; N Di Martino; G Mantovani; F Caponigro
Journal:  Breast Cancer Res Treat       Date:  1995-09       Impact factor: 4.872

5.  No synergistic activity of epirubicin and interferon-alpha 2b in the treatment of hepatocellular carcinoma.

Authors:  C Bokemeyer; B Kynast; A Harstrick; E Laage; E Schmoll; P von Wussow; H J Schmoll
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.